Menu
Subscribe - Individual
Subscribe - Biotech Premium (Corporate)
Home
About Us
Subscribe
Subscribe Individual
Subscribe Biotech Premium (Corporate)
Premium Biotech Coverage
Current News
Special Features
Company Index
Index Table
Summit
19th Bioshares Biotech Summit
Summit History
Contact
Contact Us
Email Alerts
Categories
Categories
Actinogen (ACW)
Adalta (1AD)
Amplia Therapeutics (ATX)
Anteris Technologies (AVR)
Aroa Biosurgery (ARX)
Blinklab (BB1)
Blog
Botanix (BOT)
Chimeric Therapeutics (CHM)
Clever Culture Systems (CC5)
Clinuvel Pharmaceuticals (CUV)
Cogstate (CGS)
Dimerix (DXB)
EBR Systems (EBR)
Immuron (IMC)
Imugene (IMU)
Island Pharmaceuticals (ILA)
Neuren Pharmaceuticals (NEU)
Patrys (PAB)
Syntara (SNT) (previously Pharmaxis, PXS)
Uncategorized
July 26th, 2025
Imugene to Lead with Azer-cel Program into Pivotal Study Following Additional Complete and Partial Responses. Capital Raise for up to $37.5 Million Underway
Read More
March 3rd, 2025
Complete Response Rate of 57% in Imugene's Latest Azer-Cel Phase Ib Study
Read More
December 12th, 2023
Investor Interest Starts Return to Biotech Sector (Imugene)
Read More
November 20th, 2023
First Results for Imugene's Oncolytic Virus CF33
Read More
September 4th, 2023
Imugene to Acquire Fourth Technology Platform
Read More
August 11th, 2023
2023 Bioshares Biotech Summit Coverage (Imugene)
Read More
April 6th, 2023
Imugene - Nine Clinical Programs to Advance in 2023
Read More
September 19th, 2022
Imugene to Raise $80 Million
Read More
July 5th, 2022
Imugene Releases Final Survival Data in Phase II Gastric Cancer Study
Read More
Pages
1
